Cocrystal Discovery Receives Awards for Its Novel Antiviral Drug Development Programs

Cocrystal Discovery Announces Grants totaling $733,438

SEATTLE, Nov. 3, 2010 /PRNewswire/ -- Cocrystal Discovery, Inc., a biopharmaceutical company focused on the discovery and development of novel antiviral therapeutics for the treatment of serious and chronic viral diseases, announced today that it has received $733,438 in grants from the Qualified Therapeutic Discovery Project (QTDP) administered under section 48D of the Internal Revenue Code.  The QTDP grant program provides support for innovative projects that are determined by the U.S. Department of Health and Human Services to have reasonable potential to result in a new therapy, reduce health care costs, or significantly advance the goal of curing cancer.

The QTDP grants awarded to Cocrystal are for programs in hepatitis C, influenza, and the common cold, diseases that collectively affect billions of people worldwide.

Cocrystal is a biopharmaceutical company dedicated to the development of small molecule, broad-spectrum antiviral therapeutics. The Company has laboratories in Bothell, Washington and Mountain View, California.  Cocrystal is a privately held company with headquarters in Bothell, Washington.  

SOURCE Cocrystal Discovery, Inc.

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.